E-Mail
IMAGE: Tau accumulation over one year measured in composite A) mesial temporal ROI; and B) temporoparietal ROI in cognitively unimpaired participants (blue) and cognitively impaired participants (red). The CI group included...
view more
Credit: Image created by N Krishnadas et al. Florey Department of Neurosciences & Mental Health, The University of Melbourne; Department of Molecular Imaging & Therapy, Austin Hospital, Melbourne.
Reston, VA (Embargoed until 7:30 p.m. EDT, Monday, June 14, 2021)--A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau--a distinguishing characteristic of Alzheimer's disease--before any symptoms of the disease are observed. With the potential to measure increases in tau over a long period of time, this tracer offers an important tool to assess the effectiveness of Alzheimer's disease treatments in clinical trials. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.